In light of recent clinical developments, the importance of mathematical modeling in cancer prevention and treatment is discussed. An existing model of cancer chemotherapy is reintroduced and placed within current investigative frameworks regarding approaches to treatment optimization. Areas of commonality between the model predictions and the clinical findings are investigated as a way of further validating the model predictions and also establishing mathematical foundations for the clinical studies. The model predictions are used to propose additional ways that treatment optimization could enhance the clinical processes. Arising out of these, an expanded model of cancer is proposed and a treatment model is subsequently obtained. These models predict that malignant cells in the marrow and peripheral blood exhibit the tendency to evolve toward population levels that enable them to replace normal cells in these compartments in the untreated case. In the case of dose-dense treatment along with recombinant hematopoietic growth factors, the models predict a situation in which normal and abnormal cells in the marrow and peripheral blood are obliterated by drug action, while the normal cells regain their growth capabilities through growth-factor stimulation.
Citation: Evans K. Afenya. Using Mathematical Modeling as a Resource in Clinical Trials[J]. Mathematical Biosciences and Engineering, 2005, 2(3): 421-436. doi: 10.3934/mbe.2005.2.421
Related Papers:
[1] |
Pedro José Gutiérrez-Diez, Jose Russo .
Design of personalized cancer treatments by use of optimal control problems: The case of chronic myeloid leukemia. Mathematical Biosciences and Engineering, 2020, 17(5): 4773-4800.
doi: 10.3934/mbe.2020261
|
[2] |
Katrine O. Bangsgaard, Morten Andersen, Vibe Skov, Lasse Kjær, Hans C. Hasselbalch, Johnny T. Ottesen .
Dynamics of competing heterogeneous clones in blood cancers explains multiple observations - a mathematical modeling approach. Mathematical Biosciences and Engineering, 2020, 17(6): 7645-7670.
doi: 10.3934/mbe.2020389
|
[3] |
Alacia M. Voth, John G. Alford, Edward W. Swim .
Mathematical modeling of continuous and intermittent androgen suppression for the treatment of advanced prostate cancer. Mathematical Biosciences and Engineering, 2017, 14(3): 777-804.
doi: 10.3934/mbe.2017043
|
[4] |
Rafael Martínez-Fonseca, Cruz Vargas-De-León, Ramón Reyes-Carreto, Flaviano Godínez-Jaimes .
Bayesian analysis of the effect of exosomes in a mouse xenograft model of chronic myeloid leukemia. Mathematical Biosciences and Engineering, 2023, 20(11): 19504-19526.
doi: 10.3934/mbe.2023864
|
[5] |
Svetlana Bunimovich-Mendrazitsky, Yakov Goltser .
Use of quasi-normal form to examine stability of tumor-free equilibrium in a mathematical model of bcg treatment of bladder cancer. Mathematical Biosciences and Engineering, 2011, 8(2): 529-547.
doi: 10.3934/mbe.2011.8.529
|
[6] |
Rachel Gologorsky, Sulaiman S. Somani, Sean N. Neifert, Aly A. Valliani, Katherine E. Link, Viola J. Chen, Anthony B. Costa, Eric K. Oermann .
Population scale latent space cohort matching for the improved use and exploration of observational trial data. Mathematical Biosciences and Engineering, 2022, 19(7): 6795-6813.
doi: 10.3934/mbe.2022320
|
[7] |
Abba B. Gumel, C. Connell McCluskey, James Watmough .
An sveir model for assessing potential impact of an imperfect anti-SARS vaccine. Mathematical Biosciences and Engineering, 2006, 3(3): 485-512.
doi: 10.3934/mbe.2006.3.485
|
[8] |
Dominik Wodarz .
Computational modeling approaches to studying the dynamics of oncolytic viruses. Mathematical Biosciences and Engineering, 2013, 10(3): 939-957.
doi: 10.3934/mbe.2013.10.939
|
[9] |
R. A. Everett, Y. Zhao, K. B. Flores, Yang Kuang .
Data and implication based comparison of two chronic myeloid leukemia models. Mathematical Biosciences and Engineering, 2013, 10(5&6): 1501-1518.
doi: 10.3934/mbe.2013.10.1501
|
[10] |
Zhimin Wu, Tin Phan, Javier Baez, Yang Kuang, Eric J. Kostelich .
Predictability and identifiability assessment of models for prostate cancer
under androgen suppression therapy. Mathematical Biosciences and Engineering, 2019, 16(5): 3512-3536.
doi: 10.3934/mbe.2019176
|
Abstract
In light of recent clinical developments, the importance of mathematical modeling in cancer prevention and treatment is discussed. An existing model of cancer chemotherapy is reintroduced and placed within current investigative frameworks regarding approaches to treatment optimization. Areas of commonality between the model predictions and the clinical findings are investigated as a way of further validating the model predictions and also establishing mathematical foundations for the clinical studies. The model predictions are used to propose additional ways that treatment optimization could enhance the clinical processes. Arising out of these, an expanded model of cancer is proposed and a treatment model is subsequently obtained. These models predict that malignant cells in the marrow and peripheral blood exhibit the tendency to evolve toward population levels that enable them to replace normal cells in these compartments in the untreated case. In the case of dose-dense treatment along with recombinant hematopoietic growth factors, the models predict a situation in which normal and abnormal cells in the marrow and peripheral blood are obliterated by drug action, while the normal cells regain their growth capabilities through growth-factor stimulation.